Figure 4
From: Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel
Six- and 12-month antibody signatures associated with participants in the tenofovir and placebo arms. LASSO identified a signature of eight antibody specificities that separated tenofovir (red n=13) and control groups (blue n=18) in a PLSDA model with 83% calibration accuracy and 77% cross-validation accuracy (scores plot; a). The loadings plot depicts weighted loadings of individual antibody specificities within the distinguishing signature (b). Five of these specificities were positively associated with tenofovir (negatively loaded on LV1; plasma p66 IgA at months 6 and 12, plasma p66 IgG at month 12, CVL p66 IgA at month 6, and CVL gp41 IgA at month 12) and three were negatively associated with tenofovir (positively loaded on LV1; plasma Clade C V3 linear epitope IgA at month 12, p24 IgG at month 6 and Consensus Clade C Env gp140-IgG at month 12). Latent variable 1 accounted for 24.84% and latent variable 2 accounted for 15.38% of data variance. For the analysis, only 6- and 12-month measurements were used for participants where <4% of the total data was missing. CVL, cervicovaginal lavage.
